Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Cediranib + Olaparib
Indication/Tumor Type ovary serous adenocarcinoma
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown ovary serous adenocarcinoma not applicable Cediranib + Olaparib Phase II Actionable In a Phase II trial, Cediranib (AZD-2171) and Lynparza (olaparib) treatment was well-tolerated, and resulted in an objective response (OR) of 9% (all partial), a 16-week progression-free survival (PFS) of 47%, and a disease control rate (DCR) of 68% in serous ovarian cancer patients (n=34), with an OR of 0%, 20%, 8%, 16-week PFS of 55%, 50%, 39%, and a DCR of 82%, 60%, 62% in platinum-sensitive (n=11), platinum-resistant (n=10), and exploratory cohorts (n=13), respectively (PMID: 32444417; NCT02681237). 32444417
PubMed Id Reference Title Details
(32444417) EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Full reference...